{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:41:30Z","timestamp":1794408090617,"version":"4.9.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajo.2025.08.018","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T06:39:20Z","timestamp":1755067160000},"page":"169-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Real-World Outcomes in Eyes With Neovascular AMD Switched From Brolucizumab to Faricimab: A TRUCKEE Study Analysis"],"prefix":"10.1016","volume":"280","author":[{"given":"CEREN","family":"SOYLU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9213-5575","authenticated-orcid":false,"given":"GIULIA","family":"CORRADETTI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-1660","authenticated-orcid":false,"given":"MAI","family":"ALHELALY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3203-2802","authenticated-orcid":false,"given":"HANNAH","family":"KHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AAMIR A.","family":"AZIZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HUMA","family":"KHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HAAZIQ","family":"ALI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1779-2097","authenticated-orcid":false,"given":"HUMZA","family":"SULAHRIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ARSHAD M.","family":"KHANANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-3306","authenticated-orcid":false,"given":"SRINIVAS","family":"SADDA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajo.2025.08.018_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031170","article-title":"Neovascular macular degeneration: a review of etiology, risk factors, and recent advances in research and therapy","volume":"22","author":"Pugazhendhi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajo.2025.08.018_bib0002","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2147\/OPTH.S231913","article-title":"Neovascular age-related macular degeneration (nAMD): a review of emerging treatment options","volume":"16","author":"Tan","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.08.018_bib0003","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and Neutralization of Vascular Endothelial Growth Factor (VEGF) and Related Ligands by VEGF Trap, Ranibizumab and Bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"issue":"2","key":"10.1016\/j.ajo.2025.08.018_bib0004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000513048","article-title":"Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration","volume":"244","author":"Tadayoni","year":"2021","journal-title":"Ophthalmologica"},{"issue":"7","key":"10.1016\/j.ajo.2025.08.018_bib0005","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with Brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2025.08.018_bib0006","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/IAE.0000000000003769","article-title":"Retinal vasculitis or vascular occlusion after brolucizumab for neovascular age-related macular degeneration: a systematic review of real-world evidence","volume":"43","author":"Wykoff","year":"2023","journal-title":"Retina"},{"issue":"10326","key":"10.1016\/j.ajo.2025.08.018_bib0007","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ajo.2025.08.018_bib0008","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of Faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"issue":"17","key":"10.1016\/j.ajo.2025.08.018_bib0009","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye (Lond)"},{"issue":"7","key":"10.1016\/j.ajo.2025.08.018_bib0010","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.018_bib0011","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of Brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2025.08.018_bib0012","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41433-020-1111-x","article-title":"Brolucizumab\u2014early real-world experience: BREW study","volume":"35","author":"Sharma","year":"2021","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.ajo.2025.08.018_bib0013","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00417-023-06329-1","article-title":"Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2 years: the REBA extension study","volume":"262","author":"Bilgic","year":"2024","journal-title":"Graefe's Arch Clin Exper Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.018_bib0014","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS registry and Komodo healthcare map","volume":"140","author":"Khanani","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.08.018_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100076","article-title":"TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of Faricimab for neovascular age-related macular degeneration","volume":"1","author":"Khanani","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.ajo.2025.08.018_bib0016","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/OPTH.S409822","article-title":"Initial real-world experience with Faricimab in treatment-resistant neovascular age-related macular degeneration","volume":"17","author":"Leung","year":"2023","journal-title":"Clin Ophthalmol"},{"issue":"16","key":"10.1016\/j.ajo.2025.08.018_bib0017","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","article-title":"Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy","volume":"38","author":"Goodchild","year":"2024","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.018_bib0018","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","article-title":"Short-term outcomes of Faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy","volume":"8","author":"Szigiato","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2025.08.018_bib0019","article-title":"Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study","author":"Aziz","year":"2024","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.018_bib0020","doi-asserted-by":"crossref","first-page":"9087","DOI":"10.1038\/s41598-024-59894-8","article-title":"One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment","volume":"14","author":"Takahashi","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajo.2025.08.018_bib0021","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.2147\/OPTH.S384995","article-title":"Time and distance cost of longer acting anti-VEGF therapies for macular degeneration: contributions to drug cost comparisons","volume":"16","author":"Meer","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.08.018_bib0022","article-title":"Real-world data on Faricimab switching in treatment-refractory neovascular age-related macular degeneration","volume":"14","author":"Ng","year":"2024","journal-title":"Life (Basel)"},{"issue":"6","key":"10.1016\/j.ajo.2025.08.018_bib0023","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","article-title":"Outcomes of treatment-resistant neovascular age-related macular degeneration switched from Aflibercept to Faricimab","volume":"8","author":"Raimondi","year":"2024","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"10.1016\/j.ajo.2025.08.018_bib0024","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","article-title":"Clinical outcomes of Faricimab in patients with previously treated neovascular age-related macular degeneration","volume":"8","author":"Pandit","year":"2024","journal-title":"Ophthalmol Retina"},{"issue":"10432","key":"10.1016\/j.ajo.2025.08.018_bib0025","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in Neovascular Age-related Macular Degeneration (PULSAR): 48-week Results from a Randomised, Double-masked, Non-inferiority, Phase 3 Trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ajo.2025.08.018_bib0026","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jamaophthalmol.2016.4820","article-title":"Evaluating effects of switching anti-vascular endothelial growth factor drugs for age-related macular degeneration and diabetic macular edema","volume":"135","author":"Ferris 3rd","year":"2017","journal-title":"JAMA Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425004222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425004222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:17:12Z","timestamp":1779855432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425004222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":26,"alternative-id":["S0002939425004222"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.08.018","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes in Eyes With Neovascular AMD Switched From Brolucizumab to Faricimab: A TRUCKEE Study Analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}